Related Experiment Videos
ABCG2 (BCRP) expression in normal and malignant hematopoietic cells
1Blood and Marrow Transplant Program, University of Colorado Health Science Center, Denver, CO, USA. abbottmd@StemCellTransplants.org
Hematological Oncology
|October 28, 2003
Summary
ABCG2 (BCRP) is a transporter protein found in primitive stem cells. Its role in drug resistance and potential as a stem cell marker are key areas for cancer therapy research.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- ABCG2 (BCRP) is an ATP-binding cassette transporter expressed in primitive stem cells.
- ABCG2 mediates the efflux of various substrates, including antineoplastic drugs and porphyrins.
- Its expression is linked to the side population (SP) phenotype and cytoprotection.
Purpose of the Study:
- To review the role of ABCG2 in primitive stem cells.
- To explore its potential as a stem cell marker.
- To discuss strategies for overcoming ABCG2-mediated drug resistance in cancer therapy.
Main Methods:
- Literature review of studies on ABCG2 function and expression.
- Analysis of ABCG2 substrate profiles and clinical correlations.
- Examination of the impact of ABCG2 on drug resistance and stem cell biology.
Main Results:
- ABCG2 is expressed in various normal tissues and malignancies, particularly primitive stem cells.
- Mice lacking ABCG2 show increased drug toxicity and photosensitivity.
- Despite expression in AML, ABCG2 levels do not consistently correlate with adverse outcomes.
Conclusions:
- ABCG2 plays a significant role in protecting primitive stem cells.
- It holds potential as a marker for primitive stem cells.
- Targeting ABCG2 may enhance anticancer therapy efficacy by overcoming drug resistance.